Furthermore, Edwige et al. [87] identified a crucial protein–protein interaction between ALMS1 and protein kinase C-α (PKCα), which could be a new pharmacological class for treating IR and its numerous comorbidities, such as type 2 diabetes and CVD, in large populations. Here, ALMS1 is linked to type 2 diabetes mellitus.